CO2020008308A2 - Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico - Google Patents

Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Info

Publication number
CO2020008308A2
CO2020008308A2 CONC2020/0008308A CO2020008308A CO2020008308A2 CO 2020008308 A2 CO2020008308 A2 CO 2020008308A2 CO 2020008308 A CO2020008308 A CO 2020008308A CO 2020008308 A2 CO2020008308 A2 CO 2020008308A2
Authority
CO
Colombia
Prior art keywords
relaxin
therapeutic use
chain peptides
lipidated
modified
Prior art date
Application number
CONC2020/0008308A
Other languages
English (en)
Inventor
Olivier Duclos
Stéphane Illiano
Sergio Mallart
Claire Minoletti-Hochepied
Elisabetta Bianchi
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2020008308A2 publication Critical patent/CO2020008308A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un péptido de Relaxina monocatenario biológicamente activo que tiene la siguiente fórmula (I): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-X31-X32-X33-NH2-Cter o una sal o solvato de este. También trata sobre una composición farmacéutica que comprende al menos un péptido de la invención, y el péptido o la composición farmacéutica para su uso como medicamento.
CONC2020/0008308A 2018-01-31 2020-07-06 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico CO2020008308A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
CO2020008308A2 true CO2020008308A2 (es) 2020-10-30

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0008308A CO2020008308A2 (es) 2018-01-31 2020-07-06 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Country Status (29)

Country Link
US (3) US10961295B2 (es)
EP (1) EP3746467B1 (es)
JP (1) JP7295871B2 (es)
KR (1) KR102755938B1 (es)
CN (1) CN111770934B (es)
AR (1) AR114325A1 (es)
AU (1) AU2019214358B2 (es)
BR (1) BR112020014834A2 (es)
CA (1) CA3089657A1 (es)
CO (1) CO2020008308A2 (es)
DK (1) DK3746467T3 (es)
ES (1) ES3058633T3 (es)
FI (1) FI3746467T3 (es)
HR (1) HRP20260016T1 (es)
IL (2) IL316406A (es)
LT (1) LT3746467T (es)
MA (1) MA52994A (es)
MX (1) MX2020008096A (es)
MY (1) MY199821A (es)
NZ (1) NZ766762A (es)
PH (1) PH12020551118A1 (es)
PL (1) PL3746467T3 (es)
PT (1) PT3746467T (es)
RS (1) RS67606B1 (es)
SG (1) SG11202006903WA (es)
SI (1) SI3746467T1 (es)
TW (1) TWI763972B (es)
UY (1) UY38069A (es)
WO (1) WO2019149782A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−２を調製する方法
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
EP3131925B1 (en) 2014-04-17 2020-02-19 The Florey Institute of Neuroscience and Mental Health Modified relaxin b chain peptides
JP2017513875A (ja) * 2014-04-22 2017-06-01 ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 分枝状アミノ酸プローブを有するペプチド類似体
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Also Published As

Publication number Publication date
PT3746467T (pt) 2026-01-13
JP7295871B2 (ja) 2023-06-21
PL3746467T3 (pl) 2026-04-13
EP3746467B1 (en) 2025-10-08
IL276170B1 (en) 2024-11-01
HRP20260016T1 (hr) 2026-02-27
US20210292387A1 (en) 2021-09-23
JP2021512099A (ja) 2021-05-13
LT3746467T (lt) 2026-01-26
CA3089657A1 (en) 2019-08-08
WO2019149782A1 (en) 2019-08-08
US20240218042A1 (en) 2024-07-04
MY199821A (en) 2023-11-23
KR102755938B1 (ko) 2025-01-20
MX2020008096A (es) 2020-09-24
RS67606B1 (sr) 2026-01-30
BR112020014834A2 (pt) 2020-12-08
AR114325A1 (es) 2020-08-19
TWI763972B (zh) 2022-05-11
CN111770934B (zh) 2024-10-18
AU2019214358B2 (en) 2023-05-25
MA52994A (fr) 2021-05-05
TW201940505A (zh) 2019-10-16
CN111770934A (zh) 2020-10-13
KR20200116085A (ko) 2020-10-08
US20190233494A1 (en) 2019-08-01
UY38069A (es) 2019-08-30
SG11202006903WA (en) 2020-08-28
IL276170B2 (en) 2025-03-01
EP3746467A1 (en) 2020-12-09
SI3746467T1 (sl) 2026-02-27
IL316406A (en) 2024-12-01
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
PH12020551118A1 (en) 2021-07-05
ES3058633T3 (en) 2026-03-12
US10961295B2 (en) 2021-03-30
AU2019214358A1 (en) 2020-08-20
RU2020126210A (ru) 2022-02-28
IL276170A (en) 2020-09-30
US11725036B2 (en) 2023-08-15
DK3746467T3 (da) 2026-01-12

Similar Documents

Publication Publication Date Title
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
ES2619322T3 (es) Agente inductor de inmunidad
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PE20241305A1 (es) Analogos de amilina
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
PE20160244A1 (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
MX2015015500A (es) Composiciones de cenicriviroc y metodos para elaborarlas y usarlas.
AR094178A1 (es) Derivados de exendina-4 funcionalizada
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
AR097613A1 (es) Dosificación de péptidos co-antagonistas gip/glp-1 para administración a humanos
RU2014130894A (ru) Пептид, обладающий нейропротекторной и ноотропной активностью, и фармацевтическая композиция на его основе
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.